Pure Global

Anti-SARS-CoV-2 IgG Antibody to nucleoprotein Qualitative ELISA - India CDSCO Medical Device Registration

Anti-SARS-CoV-2 IgG Antibody to nucleoprotein Qualitative ELISA is a medical device registered with India's Central Drugs Standard Control Organization (CDSCO) under UID MFG/IVD/2022/000097_6f8f4a42a03583546597b386fe71a736_16935abb314c9a615d7fc071be92d6c2. This device is marketed under the brand name Covid-19. The license holder is Krishgen Pudgala LLP, and it is classified as Device Class Class C. The approving authority is Central Drug Standards Control Organization, West Zone.

This page provides comprehensive regulatory information including complete registration details, license holder information, device classification, and related products. Pure Global AI offers free access to 71,807+ India medical device registrations, helping global MedTech companies identify partners, analyze markets, and discover business opportunities efficiently.

Free Database
Powered by Pure Global AI
CDSCO Registered
Class Class C
Anti-SARS-CoV-2 IgG Antibody to nucleoprotein Qualitative ELISA
UID: MFG/IVD/2022/000097_6f8f4a42a03583546597b386fe71a736_16935abb314c9a615d7fc071be92d6c2

Brand Name

Covid-19

License Holder

Krishgen Pudgala LLP

Device Class

Class C

Approving Authority

Central Drug Standards Control Organization, West Zone

Product Information

The GENLISAโ„ข Human Anti-SARS-CoV-2 (Covid-19) IgG ELISA kit is used as an analytical tool for qualitative estimation of IgG antibodies to Human SARS-CoV-2 (Covid-19) nucleoproteins in human serum and plasma (Covid-19)

Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing